A post-doctoral position is available immediately in the laboratory of Dr. Deborah Morrison, which is affiliated with the Laboratory of Cell and Developmental Signaling, National Cancer Institute, National Institutes of Health. Dr. Morrison’s group takes a multidisciplinary approach to study the signal transduction pathway regulated by the RAS family of GTPases. In particular, Dr. Morrison’s work focuses on the RAF kinases, which are direct effectors of RAS, and on scaffold proteins that modulate RAS pathway signaling. The RAS pathway is required for normal growth and development, and mutations in various components of the pathway can function as disease drivers in numerous human cancers as well as in a group of developmental disorders, known collectively as the RASopathies. In their research, the lab utilizes a combination of cutting-edge technologies, including bioluminescence resonance energy transfer (BRET) for the live-cell analysis of protein-protein interactions and cryoEM for the structural analysis of signaling complexes, as well as traditional methods, including mass spectrometry, cell biological assays, and biochemical techniques. These approaches are complimented by drug discovery efforts and studies in animal model systems (zebrafish). The overarching goal of the work is to further elucidate the molecular mechanisms involved in RAS-dependent signaling and to identify critical regulatory points linked to human disease states that could be targeted for therapeutic intervention.
For additional information on the Morrison lab please visit: Deborah K. Morrison, Ph.D. | Center for Cancer Research
Qualifications and Job Details
Required and Preferred Skills
Standard molecular biology, cell culture, cell imaging, and protein biochemistry techniques
Knowledge of cellular signal transduction pathways
About the NCI Center for Cancer Research
The Center for Cancer Research (CCR) is home to nearly 250 basic and clinical research groups located on two campuses just outside of Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research. We collaborate with academic and commercial partners and advocacy groups across the world in efforts to prevent, diagnose and treat cancer and HIV/AIDS. The CCR research portfolio covers the full spectrum of biological and biomedical research. Our work ranges from basic to translational and clinical, and our clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research that offers a robust infrastructure to support CCR’s patients on an estimated 250 open studies. The success of CCR is grounded in an exceptionally strong discovery research program that provides the foundation for the seamless translation of insights from bench to bedside. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Frederick is the second largest city in Maryland but retains a “small town” feel, surrounded by mountain views with a vibrant Main Street community. The city offers outstanding schools, a balanced and thriving economy and a highly educated workforce.